title: Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar).
abstract: Lonafarnib (Sarasar), a farnesyl transferase inhibitor, is currently under development for the treatment of solid tumors. Incubation of lonafarnib with human liver microsomes resulted in the formation of four oxidative metabolites (M1, M2, M3, and M4). Minor to trace levels of these metabolites were detected in humans after multiple-dose administration of lonafarnib. Liquid chromatography-mass spectrometry analyses exhibited a mass to charge ratio (m/z) for the (M+H)(+) ion of M1, M2, M3, and M4 at 653, 635, 669, and 653 Th, respectively. These metabolites, respectively, resulted from changes of +O, -2H, +2O, and +O relative to lonafarnib. Recombinant human CYP3A4 and CYP3A5 exhibited catalytic activity with respect to the formation of M1, M2, and M3, whereas CYP2C8 exhibited catalytic activity with respect to the formation of M4. There was a high correlation between the formation of M1, determined in 10 human liver microsomal samples, and 6beta-hydroxylation of testosterone catalyzed by CYP3A4/5 (r = 0.93). The IC(50) values of ketoconazole for inhibition of M1 and M2 were 0.61 and 0.92 microM, respectively. The formation of M4 by human liver microsomes was inhibited 72% by 50 microM quercetin, suggesting that the formation of M4 was mediated via CYP2C8. A CYP3A4/5-specific inhibitory monoclonal antibody inhibited the formation of M1, M2, and M3 by 85, 75, and 100%, respectively. In conclusion, the formation of metabolites M1, M2, and M3 from lonafarnib was mediated via CYP3A4 and CYP3A5.
authors.affiliation: Drug Metabolism and Pharmacokinetics, Schering-Plough Research Institute, 2015 Galloping Hill Rd., K-15-1945, Kenilworth, NJ 07033, USA. anima.ghosal@spcorp.com
authors.forename: Anima
authors.initials: A
authors.lastname: Ghosal
authors.forename: Swapan K
authors.initials: SK
authors.lastname: Chowdhury
authors.forename: Wei
authors.initials: W
authors.lastname: Tong
authors.forename: Neil
authors.initials: N
authors.lastname: Hapangama
authors.forename: Yuan
authors.initials: Y
authors.lastname: Yuan
authors.forename: Ai-Duen
authors.initials: AD
authors.lastname: Su
authors.forename: Shmuel
authors.initials: S
authors.lastname: Zbaida
mesh_terms: D000970:Antineoplastic Agents / Q000378:metabolism*; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007654:Ketoconazole / Q000494:pharmacology; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology*; D010084:Oxidation-Reduction; D010880:Piperidines / Q000378:metabolism*; D011725:Pyridines / Q000378:metabolism*; D011994:Recombinant Proteins / Q000378:metabolism; D003986:Dibenzocycloheptenes
chemical_list: D000970:Antineoplastic Agents; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System; D004791:Enzyme Inhibitors; D007654:Ketoconazole; D010880:Piperidines; D011725:Pyridines; D011994:Recombinant Proteins; C510164:CYP3A5 protein, human; C510163:CYP3A4 protein, human; C115354:lonafarnib; D003986:Dibenzocycloheptenes